Cartilage tissue differentiation

Cartilage tissue differentiation, also known as chondrogenesis, is the biological process by which mesenchymal stem cells condense and differentiate into chondrocytes, the specialized cells that produce and maintain the cartilaginous extracellular matrix (UniProt GO:0002063). This complex process is regulated by a hierarchy of signaling molecules, including bone morphogenetic proteins (BMPs) and fibroblast growth factors (FGFs), and is orchestrated by the master transcription factor SOX9 (PubMed, 2019). Cartilage differentiation is essential for skeletal development and the ongoing maintenance of articular joint surfaces, which have a very limited innate capacity for self-repair (StatPearls, 2023). In degenerative conditions such as osteoarthritis, this differentiation process is often impaired or redirected toward a hypertrophic phenotype, leading to matrix degradation and loss of joint function (NIH, 2022). Therapeutic interventions targeting this pathway aim to stimulate tissue regeneration, using agents like Sprifermin to promote chondrocyte proliferation or Lorecivivint to modulate signaling pathways in favor of cartilage formation (PubMed, 2020). Although it is a key therapeutic goal in regenerative medicine, "Cartilage tissue differentiation" describes a multi-step physiological pathway rather than a single druggable molecular target (Nature Reviews Rheumatology, 2021).

Other names

ChondrogenesisChondrocyte differentiationCartilage developmentChondrogenic differentiation

Promotion of cartilage tissue differentiation involves the activation of anabolic signaling pathways, such as the FGFR3 or TGF-beta/BMP cascades, which induce the expression of the master transcription factor SOX9. This results in the synthesis of essential extracellular matrix components, including Type II collagen and aggrecan, while suppressing catabolic enzymes (UniProt, 2023; PubMed, 2020).